Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH 2017 | Combating AML

Andrew Wei • 5 Oct 2017
ESH 2017
Acute Myeloid Leukemia Venetoclax

Andrew Wei, MBBS, PhD, FRACP, FRCPA from Alfred Hospital and Monash University, Melbourne, Australia discusses how a novel molecule, S64315, has the potential to combat acute myeloid leukaemia (AML). S64315 has started Phase I trials (NCT02979366) to assess how effective it is against the MCL-1 protein. Dr Wei also discusses the synergy of using venetoclax and other drugs targeting BCL-2 in combination with drugs targeting MCL-1 to treat AML, and how this could reduce the toxicity of the treatment. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH).

More from Andrew Wei

TP53 mutation in AML
Andrew Wei et al. • 4 Sep 2023
6:41
Clinical trials aiming to reduce the toxicity of novel agents in AML
Andrew Wei • 9 Dec 2022
6:14
Oral azacitidine maintenance in AML: QUAZAR AML-001 results after 52 months of follow-up
Andrew Wei • 15 Dec 2021
1:32
AML data at ASH 2021 and implications on clinical practice
Andrew Wei • 15 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals